Key result
COVID-19 viral myocarditis reports remain largely anecdotal and lack definitive biopsy-proven myocyte invasion.
Why the study?
Myocardial injury is observed in 7-28% of COVID-19 patients and is associated with increased morbidity and mortality, but the existence of COVID-19 associated viral myocarditis is unclear.
Highlights that myocardial injury occurs in 7-28% of COVID-19 patients and is associated with worse clinical outcomes.
Answers are grounded in this paper and cite their sources.
Troponin elevation flags higher-risk COVID-19 patients for closer monitoring; leaves open whether targeted cardiac interventions improve outcomes.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a lethal pandemic that has claimed millions of lives worldwide. While respiratory involvement is the most common and most virulent manifestation of COVID-19, there is enough data to suggest that myocardial injury reflected through elevated troponin levels is seen in around 7-28% of patients and is related with increased morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2020) conducted a review in COVID-19 associated viral myocarditis. SARS-CoV-2 infection was evaluated. Available data regarding the occurrence of viral myocarditis in COVID-19 is anecdotal, lacking definitive endomyocardial biopsy documentation of SARS-CoV-2 invading myocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: